ERN1 and metabolic dysfunction-associated steatotic liver disease: Additionally, studies with IRE1 and ATF6 in MASLD are warranted to determine the effects of IRE1 or ATF6 inhibitors on MASLD and to identify new targeted drugs for this scenario.